Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertapenem Sodium

FDA-approved product (injectable, intramuscular, intravenous), marketed as Ertapenem Sodium, Invanz.

Registered studies
50+
Lab records
186
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ertapenem Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial pneumonia
  • Community-Acquired Infections
  • Gram-negative bacterial infections
  • Infection
  • Osteomyelitis
  • Staphylococcal skin infections
  • Streptococcal infection
  • Surgical Wound Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH03

Repurposing investigation

Ertapenem Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • K. pneumoniae99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 141 of 186 lab records
Open Ertapenem Sodium in ChEMBL Registered studies below
Show the latest 150 of 186 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertapenem Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis

    NCT00097734 · start 2004-07

    Registered record
    Registry ID
    NCT00097734
    Conditions
    Diverticulitis, Colonic; Acute Disease
    Interventions
    ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2004-07
    Completion
    2007-06
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiverticulitis, Colonic; Acute Disease
    Interventionertapenem
    PhasePhase 4
    Registry statusUnknown

  • An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)

    NCT00092170 · start 2002-03

    Registered record
    Registry ID
    NCT00092170
    Conditions
    Infections; Pelvic Infections
    Interventions
    MK0826, ertapenem sodium; Comparator: Ticarcillin/Clavulanate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-03
    Completion
    2004-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections; Pelvic Infections
    InterventionMK0826, ertapenem sodium; Comparator: Ticarcillin/Clavulanate
    PhasePhase 2
    Registry statusCompleted

  • Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

    NCT00451386 · start 2002-01

    Registered record
    Registry ID
    NCT00451386
    Conditions
    Urinary Tract Infections; Bacterial Pneumonia; Soft Tissue Infections
    Interventions
    MK0826, ertapenem sodium /Duration of Treatment: 14 Days; Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    2003-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Bacterial Pneumonia; Soft Tissue Infections
    InterventionMK0826, ertapenem sodium /Duration of Treatment: 14 Days; Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days
    PhasePhase 2
    Registry statusCompleted

  • Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

    NCT00389987 · start 2001-09

    Registered record
    Registry ID
    NCT00389987
    Conditions
    Complicated Intra-Abdominal Infections
    Interventions
    MK0826, /Duration of Treatment : 8 Weeks; Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-09
    Completion
    2004-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-Abdominal Infections
    InterventionMK0826, /Duration of Treatment : 8 Weeks; Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Ertapenem Distribution in the Muscle of Six Healthy Volunteers and Six Critically Ill Patients by Microdialysis

    NCT01061047

    Registered record
    Registry ID
    NCT01061047
    Conditions
    Healthy
    Interventions
    Ertapeneme
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionErtapeneme
    PhasePhase 1
    Registry statusCompleted